Structure Therapeutics (NASDAQ:GPCR) Stock Price Down 8.1% – Time to Sell?

Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR)’s stock price traded down 8.1% during mid-day trading on Tuesday . The company traded as low as $43.98 and last traded at $43.5260. Approximately 751,091 shares were traded during mid-day trading, a decline of 14% from the average session volume of 872,345 shares. The stock had previously closed at $47.34.

Analyst Ratings Changes

Several brokerages have issued reports on GPCR. Citizens Jmp dropped their price objective on shares of Structure Therapeutics from $113.00 to $110.00 and set a “market outperform” rating on the stock in a research note on Friday, August 7th. HC Wainwright lowered their target price on shares of Structure Therapeutics from $100.00 to $70.00 and set a “buy” rating on the stock in a report on Thursday, June 11th. Canaccord Genuity Group set a $111.00 price target on Structure Therapeutics in a report on Friday, August 7th. Wall Street Zen upgraded Structure Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Monday, August 17th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Structure Therapeutics in a research report on Friday, July 17th. Two research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $110.91.

Structure Therapeutics Price Performance

The firm has a market cap of $2.97 billion, a PE ratio of -42.88 and a beta of -1.45. The business has a 50-day moving average price of $50.68 and a two-hundred day moving average price of $49.21.

Structure Therapeutics (NASDAQ:GPCR) last issued its quarterly earnings data on Thursday, August 6th. The company reported ($0.49) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.10). Equities analysts expect that Structure Therapeutics Inc. Sponsored ADR will post -1.84 earnings per share for the current fiscal year.

Institutional Trading of Structure Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the business. Seven Fleet Capital Management LP increased its holdings in shares of Structure Therapeutics by 197.8% during the 2nd quarter. Seven Fleet Capital Management LP now owns 26,800 shares of the company’s stock worth $1,442,000 after buying an additional 17,800 shares during the last quarter. Wellington Management Group LLP increased its stake in Structure Therapeutics by 1.6% during the second quarter. Wellington Management Group LLP now owns 7,379,433 shares of the company’s stock worth $396,054,000 after acquiring an additional 119,146 shares during the last quarter. Handelsbanken Fonder AB acquired a new stake in Structure Therapeutics during the second quarter worth about $1,041,000. Avidity Partners Management LP acquired a new position in shares of Structure Therapeutics in the 1st quarter valued at about $1,446,000. Finally, Bank of America Corp DE grew its holdings in shares of Structure Therapeutics by 617.0% during the 1st quarter. Bank of America Corp DE now owns 227,132 shares of the company’s stock worth $10,948,000 after purchasing an additional 195,454 shares during the period. 91.78% of the stock is owned by institutional investors and hedge funds.

About Structure Therapeutics

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.